These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 21513851)
1. The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma. Zhang Y; He N; Zhou J; Chen Y Clin Imaging; 2011; 35(3):165-73. PubMed ID: 21513851 [TBL] [Abstract][Full Text] [Related]
2. CD147 expression in pituitary adenomas and its significance for clinical outcome. Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119 [TBL] [Abstract][Full Text] [Related]
3. Extracellular matrix metalloproteinase inducer expression in salivary gland tumors: a correlation with microvessel density. Huang ZQ; Chen WL; Li HG; Li JS; Xu ZY; Lin ZY J Craniofac Surg; 2010 Nov; 21(6):1855-60. PubMed ID: 21119439 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of magnetic resonance imaging criteria for cavernous sinus invasion in patients with pituitary adenomas: logistic regression analysis and correlation with surgical findings. Vieira JO; Cukiert A; Liberman B Surg Neurol; 2006 Feb; 65(2):130-5; discussion 135. PubMed ID: 16427401 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Niveiro M; Aranda FI; Peiró G; Alenda C; Picó A Hum Pathol; 2005 Oct; 36(10):1090-5. PubMed ID: 16226108 [TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918 [TBL] [Abstract][Full Text] [Related]
8. MR imaging of cavernous sinus involvement by pituitary adenomas. Scotti G; Yu CY; Dillon WP; Norman D; Colombo N; Newton TH; De Groot J; Wilson CB AJR Am J Roentgenol; 1988 Oct; 151(4):799-806. PubMed ID: 3262283 [TBL] [Abstract][Full Text] [Related]
9. Expression of survivin in invasive pituitary adenoma. Zhang YC; Gao J; Xin T; Zheng ZM; Teng LZ Saudi Med J; 2008 Nov; 29(11):1589-92. PubMed ID: 18998006 [TBL] [Abstract][Full Text] [Related]
10. [MRI diagnosis of sinus cavernous invasion by pituitary adenomas]. Moreau L; Cottier JP; Bertrand P; Destrieux C; Jan M; Sonier CB; Herbreteau D; Rouleau P J Radiol; 1998 Mar; 79(3):241-6. PubMed ID: 9757244 [TBL] [Abstract][Full Text] [Related]
11. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior]. He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658 [TBL] [Abstract][Full Text] [Related]
13. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800 [TBL] [Abstract][Full Text] [Related]
14. [Expression of pituitary tumor transforming gene, endostatin, and basic fibroblast growth factor mRNAs in invasive pituitary adenomas]. Chen L; Liu YS; Wang LS; Yin HG; Hou QT; Liu ZX; Chen LH; Ling F Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):651-3, 666. PubMed ID: 16114549 [TBL] [Abstract][Full Text] [Related]
16. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Righi A; Morandi L; Leonardi E; Farnedi A; Marucci G; Sisto A; Frank G; Faustini-Fustini M; Zoli M; Mazzatenta D; Agati R; Foschini MP Hum Pathol; 2013 Nov; 44(11):2400-9. PubMed ID: 24007691 [TBL] [Abstract][Full Text] [Related]
17. Assessment of normal perisellar anatomy in 1.5 T T2-weighted MRI and comparison with the anatomic criteria defining cavernous sinus invasion of pituitary adenomas. Knappe UJ; Jaursch-Hancke C; Schönmayr R; Lörcher U Cent Eur Neurosurg; 2009 Aug; 70(3):130-6. PubMed ID: 19701871 [TBL] [Abstract][Full Text] [Related]
18. Expression and clinical significance of CD147 in genitourinary carcinomas. Han ZD; He HC; Bi XC; Qin WJ; Dai QS; Zou J; Ye YK; Liang YX; Zeng GH; Zhu G; Chen ZN; Zhong WD J Surg Res; 2010 May; 160(2):260-7. PubMed ID: 19286191 [TBL] [Abstract][Full Text] [Related]
19. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas. Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830 [TBL] [Abstract][Full Text] [Related]
20. [Expression of galectin-3 in invasive prolactinomas]. Wang H; Wang MD; Ma WB; Yang D; Shi YF; Kong YG; Li SF; Li ZH; Wang RZ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):380-1. PubMed ID: 16038281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]